The genomic landscape of cutaneous melanoma
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Summary: Somatic mutation analysis of melanoma has been performed at the single gene level extensively over the past several decades. This has provided considerable insight into the critical pathways controlling melanoma initiation and progression. During the last 5 yr, next‐generation sequencing (NGS) has enabled even more comprehensive mutational screening at the level of multigene panels, exomes and genomes. These studies have uncovered many new and unexpected players in melanoma development. The recent landmark study from The Cancer Genome Atlas (TCGA) consortium describing the genomic architecture of 333 cutaneous melanomas provides the largest and broadest analysis to date on the somatic aberrations underlying melanoma genesis. It thus seems timely to review the mutational landscape of melanoma and highlight the key genes and cellular pathways that appear to drive this cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674 · cited 2×
“The discovery of frequent BRAF mutations in melanomas (Davies et al., 2002) and melanocytic nevi (Pollock et al., 2003) provided the initial opportunity to search for genetic differences between tumors arising on skin with or without evidence of chronic sun damage (based on the presence or absence…”
BackgroundSignatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660 · cited 3×
“An alternative approach to separate tumors into subgroups with potentially different UVR exposure patterns is assessment of the proportion of mutations within a tumor that could be ascribed to UVR mutagenesis, for example C>T or CC>TT mutations, or perhaps more precisely in the context of a mutational signature based…”
BackgroundMutational heterogeneity in cancer and the search for new cancer-associated genes
Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., et al. (2013) · Nature · doi:10.1038/nature12213 · Cited by 5,461
Genomic classification of cutaneous melanoma
Akbani, R., Akdemir, K. C., Aksoy, B. A., Albert, M., Ally, A., Amin, S. B., Arachchi, H., Arora, A., Auman, J. T., Ayala, B., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.044 · Cited by 3,151 · cited 21×
“An imperfect surrogate for UVR exposure that can be evaluated in most datasets is body site of primary tumor and is available for a subset of the TCGA melanomas (Watson et al., 2015).”
BackgroundResultInfluentialSelf-citationDiscovery and saturation analysis of cancer genes across 21 tumour types
Lawrence, M. S., Stojanov, P., Mermel, C. H., Robinson, J. T., Garraway, L. A., Golub, T. R., Meyerson, M., Gabriel, S. B., Lander, E. S., & Getz, G. (2014) · Nature · doi:10.1038/nature12912 · Cited by 3,096
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
Van Allen, E. M., Miao, D., Schilling, B., Shukla, S. A., Blank, C., Zimmer, L., Sucker, A., Hillen, U., Geukes Foppen, M. H., Goldinger, S. M., et al. (2015) · Science · doi:10.1126/science.aad0095 · Cited by 2,839 · cited 1×
“High somatic mutation burden in melanoma has already been linked to favorable outcomes of immune-based therapeutic approaches using CTLA-4 antibodies (Snyder et al., 2014; Van Allen et al., 2015).”
BackgroundA cell cycle regulator potentially involved in genesis of many tumor types
Kamb, A., Gruis, N. A., Weaver-Feldhaus, J., Liu, Q., Harshman, K., Tavtigian, S. V., Stockert, E., Day, R. S., Johnson, B. E., & Skolnick, M. H. (1994) · Science · doi:10.1126/science.8153634 · Cited by 2,751
Distinct Sets of Genetic Alterations in Melanoma
Curtin, J. A., Fridlyand, J., Kageshita, T., Patel, H. N., Busam, K. J., Kutzner, H., Cho, K.-H., Aiba, S., Bröcker, E.-B., LeBoit, P. E., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050092 · Cited by 2,747
A landscape of driver mutations in melanoma
Hodis, E., Watson, I. R., Kryukov, G. V., Arold, S. T., Imielinski, M., Theurillat, J.-P., Nickerson, E., Auclair, D., Li, L., Place, C., et al. (2012) · Cell · doi:10.1016/j.cell.2012.06.024 · Cited by 2,610 · cited 15×
“…number of melanomas included 121 tumors and introduced a statistical approach to identify SMGs based on predicted functional impact of the mutations as well as ‘local’ mutation rate (i.e. relative abundance of mutations between exons and introns/UTRs of the same gene) (Hodis et al., 2012).”
BackgroundMethodResultInfluentialTERT Promoter Mutations in Familial and Sporadic Melanoma
Horn, S., Figl, A., Rachakonda, P. S., Fischer, C., Sucker, A., Gast, A., Kadel, S., Moll, I., Nagore, E., Hemminki, K., et al. (2013) · Science · doi:10.1126/science.1230062 · Cited by 1,799 · cited 5×
“…comes from a simultaneous report of both germline and somatic TERT promoter mutations in melanomas, in which two additional recurrent tandem GG>AA (CC>TT) somatic mutations generating ETS binding sites were reported at positions chr5:1295228/ 1295229 and chr5:1295242/1295243 (Horn et al., 2013).”
BackgroundResultInfluentialDeletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers
Nobori, T., Miura, K., Wu, D. J., Lois, A., Takabayashi, K., & Carson, D. A. (1994) · Nature · doi:10.1038/368753a0 · Cited by 1,742
High frequency of BRAF mutations in nevi
Pollock, P. M., Harper, U. L., Hansen, K. S., Yudt, L. M., Stark, M., Robbins, C. M., Moses, T. Y., Hostetter, G., Wagner, U., Kakareka, J., et al. (2003) · Nature Genetics · doi:10.1038/ng1054 · Cited by 1,730 · cited 2×
“The discovery of frequent BRAF mutations in melanomas (Davies et al., 2002) and melanocytic nevi (Pollock et al., 2003) provided the initial opportunity to search for genetic differences between tumors arising on skin with or without evidence of chronic sun damage (based on the presence or absence…”
BackgroundSelf-citationA comprehensive catalogue of somatic mutations from a human cancer genome
Pleasance, E. D., Cheetham, R. K., Stephens, P. J., McBride, D. J., Humphray, S. J., Greenman, C. D., Varela, I., Lin, M.-L., Ordóñez, G. R., Bignell, G. R., et al. (2010) · Nature · doi:10.1038/nature08658 · Cited by 1,696 · cited 2×
“The first report describing a catalog of somatic mutation events in cancer was from a commercially available melanoma cell line that was published in 2010 (Pleasance et al., 2010).”
BackgroundGarraway, L. A., Widlund, H. R., Rubin, M. A., Getz, G., Berger, A. J., Ramaswamy, S., Beroukhim, R., Milner, D. A., Granter, S. R., Du, J., et al. (2005) · Nature · doi:10.1038/nature03664 · Cited by 1,548 · cited 1×
“Garraway et al. (2005) initially reported amplification of the MITF locus in approximately 10% of primary melanomas, with a higher observed frequency in metastases (21%).”
BackgroundExome sequencing identifies recurrent somatic RAC1 mutations in melanoma
Krauthammer, M., Kong, Y., Ha, B. H., Evans, P., Bacchiocchi, A., McCusker, J. P., Cheng, E., Davis, M. J., Goh, G., Choi, M., et al. (2012) · Nature Genetics · doi:10.1038/ng.2359 · Cited by 1,191 · cited 18×
“RAC1 is a small G-protein member of the Rac subfamily of Rho GTPases that regulate cellular events including activation of protein kinases.”
BackgroundResultInfluentialSelf-citationGermline mutations in the p16INK4a binding domain of CDK4 in familial melanoma
Zuo, L., Weger, J., Yang, Q., Goldstein, A. M., Tucker, M. A., Walker, G. J., Hayward, N., & Dracopoli, N. C. (1996) · Nature Genetics · doi:10.1038/ng0196-97 · Cited by 818 · cited 1×
“Similarly, the discovery of hotspot mutations in the p16-binding domain of CDK4 in melanoma families (Zuo et al., 1996) followed the discovery of similar mutations in melanoma tumors (W€olfel et al., 1995).”
BackgroundSelf-citationMelanoma genome sequencing reveals frequent PREX2 mutations
Berger, M. F., Hodis, E., Heffernan, T. P., Deribe, Y. L., Lawrence, M. S., Protopopov, A., Ivanova, E., Watson, I. R., Nickerson, E., Ghosh, P., et al. (2012) · Nature · doi:10.1038/nature11071 · Cited by 756 · cited 5×
“PREX2 gene mutations were observed in approximately 27% of TCGA melanomas, a somewhat higher frequency than the 14% mutation rate originally reported (Berger et al., 2012; Watson et al., 2015).”
BackgroundResultInfluentialDeterminants of BRAF Mutations in Primary Melanomas
Maldonado, J. L., Fridlyand, J., Patel, H., Jain, A. N., Busam, K., Kageshita, T., Ono, T., Albertson, D. G., Pinkel, D., & Bastian, B. C. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djg123 · Cited by 664
Enhancer hijacking activates GFI1 family oncogenes in medulloblastoma
Northcott, P. A., Lee, C., Zichner, T., Stütz, A. M., Erkek, S., Kawauchi, D., Shih, D. J. H., Hovestadt, V., Zapatka, M., Sturm, D., et al. (2014) · Nature · doi:10.1038/nature13379 · Cited by 642
The transcription factor GABP selectively binds and activates the mutant TERT promoter in cancer
Bell, R. J. A., Rube, H. T., Kreig, A., Mancini, A., Fouse, S. D., Nagarajan, R. P., Choi, S., Hong, C., He, D., Pekmezci, M., et al. (2015) · Science · doi:10.1126/science.aab0015 · Cited by 566 · cited 1×
“Recently, Bell et al. (2015) showed that GABP is the specific ETS transcription factor that binds to the mutated motifs in the TERT promoter, a finding since replicated in melanoma (Makowski et al., 2015).”
BackgroundGenome-wide analysis of noncoding regulatory mutations in cancer
Weinhold, N., Jacobsen, A., Schultz, N., Sander, C., & Lee, W. (2014) · Nature Genetics · doi:10.1038/ng.3101 · Cited by 484 · cited 2×
“…of the same melanoma WGS data as above, but in the context of a pan-cancer analysis of 863 tumors of diverse types, identified the chr5:1295228 and chr5:1295250 TERT promoter mutations in 10 of 17 melanomas and showed that the mutations resulted in increased TERT expression (Weinhold et al., 2014).”
BackgroundCTCF/cohesin-binding sites are frequently mutated in cancer
Katainen, R., Dave, K., Pitkänen, E., Palin, K., Kivioja, T., Välimäki, N., Gylfe, A. E., Ristolainen, H., Hänninen, U. A., Cajuso, T., et al. (2015) · Nature Genetics · doi:10.1038/ng.3335 · Cited by 447
Brash, D. E. (2015) · Photochemistry and Photobiology · doi:10.1111/php.12377 · Cited by 401 · cited 1×
“Analysis by TCGA using the former approach, specifically the criteria proposed by Brash (2015) (> 60% C>T transitions or >5% CC>TT) to classify samples as ª 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd 275 associated with high-UVR, revealed no distinct difference between samples…”
MethodPOT1 loss-of-function variants predispose to familial melanoma
Robles-Espinoza, C. D., Harland, M., Ramsay, A. J., Aoude, L. G., Quesada, V., Ding, Z., Pooley, K. A., Pritchard, A. L., Tiffen, J. C., Petljak, M., et al. (2014) · Nature Genetics · doi:10.1038/ng.2947 · Cited by 391 · cited 3×
“To date, rare, high-penetrance mutations to multiple genes involved in telomere maintenance have been identified in multiple-case melanoma families, including mutations to the TERT promoter (Harland et al., 2015; Horn et al., 2013), as well as to the protein-coding sequence of the shelterin complex members POT1 (Roble…”
BackgroundInfluentialSelf-citationAnalysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4
Program, N. C. S., Prickett, T. D., Agrawal, N. S., Wei, X., Yates, K. E., Lin, J. C., Wunderlich, J. R., Cronin, J. C., Cruz, P., Rosenberg, S. A., et al. (2009) · Nature Genetics · doi:10.1038/ng.438 · Cited by 352 · cited 2×
“While there is considerable evidence that multiple RTKs upstream of these pathways play significant roles in melanoma biology, relatively few show frequent somatic genetic alterations (Prickett et al., 2009).”
BackgroundMC1R variants, melanoma and red hair color phenotype: A meta‐analysis
Raimondi, S., Sera, F., Gandini, S., Iodice, S., Caini, S., Maisonneuve, P., & Fargnoli, M. C. (2008) · International Journal of Cancer · doi:10.1002/ijc.23396 · Cited by 349
Rare missense variants in POT1 predispose to familial cutaneous malignant melanoma
NCI DCEG Cancer Sequencing Working Group, Shi, J., Laboratory, N. D. C. G. R., French Familial Melanoma Study Group, Yang, X. R., Ballew, B., Rotunno, M., Calista, D., Fargnoli, M. C., Ghiorzo, P., et al. (2014) · Nature Genetics · doi:10.1038/ng.2941 · Cited by 331
Integrative analysis of the melanoma transcriptome
Berger, M. F., Levin, J. Z., Vijayendran, K., Sivachenko, A., Adiconis, X., Maguire, J., Johnson, L. A., Robinson, J., Verhaak, R. G., Sougnez, C., et al. (2010) · Genome Research · doi:10.1101/gr.103697.109 · Cited by 305 · cited 1×
“The use of RNA-seq has also been used to identify gene fusions in melanoma (Berger et al., 2010).”
MethodAmplification of CDK4 and MDM2 in malignant melanoma
Muthusamy, V., Hobbs, C., Nogueira, C., Cordon‐Cardo, C., McKee, P. H., Chin, L., & Bosenberg, M. W. (2006) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20310 · Cited by 148
Recurrent inactivating RASA2 mutations in melanoma
Arafeh, R., Qutob, N., Emmanuel, R., Keren-Paz, A., Madore, J., Elkahloun, A., Wilmott, J. S., Gartner, J. J., Di Pizio, A., Winograd-Katz, S., et al. (2015) · Nature Genetics · doi:10.1038/ng.3427 · Cited by 107
Self-citation
Cited by
Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., Prieto, P. A., Vicente, D., Hoffman, K., Wei, S. C., et al. (2018) · Science · doi:10.1126/science.aan4236 · Cited by 4,812
Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic Melanoma
Gide, T. N., Wilmott, J. S., Scolyer, R. A., & Long, G. V. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2267 · Cited by 454
Formation of UV-induced DNA damage contributing to skin cancer development
Cadet, J., & Douki, T. (2018) · Photochemical & Photobiological Sciences · doi:10.1039/c7pp00395a · Cited by 435
Luebker, S. A., & Koepsell, S. A. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00268 · Cited by 194
Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma
Reuben, A., Spencer, C. N., Prieto, P. A., Gopalakrishnan, V., Reddy, S. M., Miller, J. P., Mao, X., De Macedo, M. P., Chen, J., Song, X., et al. (2017) · npj Genomic Medicine · doi:10.1038/s41525-017-0013-8 · Cited by 166
Metadata
- Authors
- Zhang, T., Dutton‐Regester, K., Brown, K. M., & Hayward, N. K.
- Venue
- Pigment Cell & Melanoma Research
- Publisher
- Wiley
- Published
- 2016-03-04
- Volume
- 29
- Issue
- 3
- Pages
- 266-283
- ISSN
- 1755-1471 (ISSN-L)
- 1755-148X
- OpenAlex
- W2294698383
- Cited by
- 172
- References
- 30
- FWCI
- 10.53
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.